GLG News by Medical Device Experts

The at-risk product launch by [NasdaqGS:TEVA] Teva of generic equivalents to [NYSE:PFE] Pfizer's Neurontin® (gabapentin) might - and the emphasis is clearly on might - yet prove to be an expensive mistake by Teva. The recent Opinion by the United States Court of Appeals for the Federal Circuit...

In my prior Tue 31 Jul 2007 Analysis available here http://news.glgroup.com/CM/Analysis/PostDetail.aspx?pid=14722 I stated: The upcoming Altace ® Opinion will most likely fall in line with this noted trend. In other words, King Pharmaceutical [NYSE:KG]'s patent protection for Altace ® (ramipril)...

Japanese companies and authorities are waiting for what FDA decides.

With respect to the blockbuster antidepressant drug Lexapro®, the US Court of Appeals for the Federal Circuit, CAFC or Fed Cir, affirmed the prior November, 2006 Opinion of the Delaware District Court with respect to Plaintiff Forest Labs (NYSE:FRX) Paragraph (IV) patent infringement litigation...

Managed Medicaid is not a new concept. Over the last two decades, many states have implemented Managed Medicaid programs under the Centers for Medicare and Medicaid Services (CMS) 1115b Waiver program. The waiver program allowed states to implement Managed Medicaid programs as demonstration projects. Medicaid...

The results of two Phase III trials conducted by Novo Nordisk on liraglutide, a once-daily dosed GLP-1 analog, indicate significant glucose lowering efficacy and weight loss. On a positive note, Novo has to be relieved that they are seeing the same magnitude of HbA1c reduction and weight loss...

KSR involved mechanical technologies, but its rulings apply to all different arts, including biotechnology, medical devices, and pharmaceuticals.  The applications of KSR analysis by the Federal Circuit are multiplying and the results are not in favor of patent owners, including those patent...

The Centers for Medicare and Medicaid Services has proposed a 9.9% cut in payment to physicians for 2008. This is a very real possibility and results from a legislative requirement that the Agency is required to act upon. Congress has stepped in each year for the last five years to counteract reductions...

I was trained on the use of New-fill in London about 5 years ago. My impression then was of a rather complicated to use product, compared to the existing fillers in the market like Hyaluronic Acid.

July 19 the House Judiciary Committee will hold hearings on credit card interchange fees.  Will these hearings lead to renewed antitrust enforcement?  Will the card associations provide a strong justification for interchange?  How will Congressmen respond to the fact that interchange...